Evidence library 22 analyses
A SIRT6 research hub covering the biology of this longevity-linked protein, activator compounds and the gap between mechanism and human evidence.
Complete library
Browse every published guide, review and evidence update in this topic.
SIRT6 can be targeted with gene therapy, allosteric activators, inhibitors and experimental peptides. See AAV research, MDL-800, UBCS039, forvisirvat and why inhibition can also matter.
SIRT6 vs NMN explained: one is an NAD+-dependent enzyme target, the other an NAD+ precursor. Compare human trials, DNA repair, longevity evidence and overlap.
Compare SIRT1, SIRT3 and SIRT6 by cellular location, function, activators, NAD+ dependence and longevity evidence. They share a family—not the same biology.
SIRT6 suppresses NF-kappaB genes and LINE1 retrotransposons in experimental models. See how cGAS signaling connects genome instability to inflammaging.
SIRT6 supports brain DNA repair and mitochondria in animal models. See Alzheimer’s tissue findings, Tau biology, forvisirvat CNS data and what human treatment evidence is missing.
SIRT6 can suppress tumors in some models yet support growth in others. Review MDL-800, UBCS039, cancer metabolism, immune surveillance and what human evidence does not show.
SIRT6 supports muscle metabolism, AMPK and oxidative fibers in animal studies. See human exercise associations, activator data and what performance claims remain unproven.
SIRT6 regulates glucose, HIF-1alpha, insulin sensitivity and liver lipid metabolism in preclinical research. See what human and activator studies actually support.
Which polyphenols activate SIRT6? Compare cyanidin, quercetin, luteolin, resveratrol and structure-dependent effects from biochemical and cellular research.
